Facet Life Sciences, a provider of US regulatory strategy and product development solutions for the life sciences industry, announced on Wednesday that it will serve as the US regulatory partner for Canada-based neuropsychiatry company Cybin Inc.

The partnership will support Cybin's work in next generation therapeutics, particularly for conditions such as Major Depressive Disorder, Generalised Anxiety Disorder and Central Nervous system disorders.

Facet Life Sciences will guide Cybin's development programmes to and through the US Food and Drug Administration (FDA) review and approval process.

Ken VanLuvanee, Facet Life Sciences' founder and CEO, said: "We are excited to collaborate with Cybin as their regulatory partner, supporting their mission to redefine mental health treatment through innovation. Cybin's approach aligns with our mission to help advance groundbreaking therapeutics while meeting the highest regulatory standards, including our desire to bring efficacious and safe therapeutics to patients suffering with various neuropsychiatric diseases."